

Medical Marketing

LIVE WEBINAR

Friday, August 7, 2020 • 12:00 PM ET/9:00 AM PT


Register now

# Cardiovascular Clinical Conversations: Understanding the function of HDL— beyond its levels

Presented by:

## James L. Januzzi, MD

Hutter Family Professor of Medicine, Harvard Medical School  
Cardiologist, Massachusetts General Hospital  
Senior Cardiometabolic Faculty, Baim Institute for Clinical Research  
Boston, Massachusetts



To register for this live webinar, please visit:  
[QuestDiagnostics.com/EventRegistration](https://QuestDiagnostics.com/EventRegistration)

Please note: Advance registration is required for participation.

Current evidence supports a causal association between low HDL-C (high-density lipoprotein cholesterol) and cardiovascular risk, and that therapeutic targeting of low HDL-C may be beneficial. However, multiple clinical trials for therapies that increase HDL-C levels have failed to produce positive results. These failed clinical trials have led to the consensus that understanding the function of HDL—not just its levels—is needed to determine and develop effective treatment.

We invite you to join us for a discussion on:

- What is known about HDL and its role in atherosclerosis?
- A novel tool that allows for rapid assessment of HDL function for use in clinical practice
- The relation of the HDLfx panel with pCAD score to other cardiovascular risk markers
- A clinical perspective of HDLfx

For more information, contact your Quest Diagnostics representative or email [EducationalEvents@QuestDiagnostics.com](mailto:EducationalEvents@QuestDiagnostics.com).

Visit [QuestDiagnostics.com/Education](https://QuestDiagnostics.com/Education) to view on demand webinars.

Contact us:

Quest Diagnostics • 500 Plaza Drive • Secaucus, New Jersey 07094 • Attention: Medical Marketing

Dr Januzzi is a clinician, teacher and clinical trialist. His research has contributed extensively to the understanding of cardiac biomarker testing, where his studies have set international standards for use in diagnosis, prognosis, and management of patients suffering from heart failure and acute coronary syndromes. He has done pioneering studies on NT-proBNP, high sensitivity troponin, galectin-3, and ST2, along with more recent work focused on targeted proteomics. Dr Januzzi has published more than 600 manuscripts, book chapters, and review articles, and has edited 6 text books. He is among the top 1% most cited researchers, according to Clarivate/Web of Science. Dr Januzzi is also an associate editor at both *Journal of the American College of Cardiology* and *Journal of the American College of Cardiology: Heart Failure*.

Quest, Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the registered trademarks of Quest Diagnostics.

©2020 Quest Diagnostics Incorporated. All rights reserved. MI9569 7/2020

This communication is intended for healthcare professionals in the USA.

[Unsubscribe from updates.](#)